Inhibition of jak1,2 prevents fibrotic remodeling of pulmonary vascular bed and improves outcomes in the rat model of chronic thromboembolic pulmonary hypertension

HIGHLIGHTS

• who: Andrei A. Karpov et al. from the Institute of Experimental Medicine, Almazov National Medical Research Centre, Saint Petersburg, Russia Center of Experimental Pharmacology, Saint Petersburg State Chemical Pharmaceutical University have published the research work: Inhibition of JAK1,2 Prevents Fibrotic Remodeling of Pulmonary Vascular Bed and Improves Outcomes in the Rat Model of Chronic Thromboembolic Pulmonary Hypertension, in the Journal: (JOURNAL)
• what: This study demonstrated that JAK1/2 inhibitor ruxolitinib dose-dependently reduced pulmonary vascular remodeling thereby preventing CTEPH formation in rats. The aim of this work is to study the antifibrotic effect of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.